Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2377-2386

  Yamagishi, Sho ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cardiometabolic disorders; Oxidative stress; PEDF

Indexed keywords

INSULIN; PIGMENT EPITHELIUM DERIVED FACTOR; BIOLOGICAL MARKER; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; CARDIOMETABOLIC DISORDER; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FATTY LIVER; HEPATITIS; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIAGNOSTIC USE; HYPERTENSION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EYE PROTEINS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; NERVE GROWTH FACTORS; SERPINS;

EID: 84903701078     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990473     Document Type: Article

References (154)

1. Fernandes-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endoc Rev 2003; 24: 278-301.
2. Fong TM. Targeting metabolic syndrome. Expert Opin Investig Drugs 2004; 13: 1203-6.
3. Kampoli AM, Tousoulis D, Briasoulis A, et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011; 17: 4147-58.
4. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005; 47: 201-10.
5. Yamagishi S. Cardiovascular disease in recent onset diabetes mellitus. J Cardiol 2011; 57: 257-62.
6. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab 2009; 10: 159-63.
7. Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010; 17: 4511-20.
8. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med 1999; 340: 115-26.
9. Introna M, Mantovani A. Early activation signals in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 423-8.
10. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
11. Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med 2006; 6: 501-14.
12. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8: 1138-43.
13. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008, 15: 172-8.
14. Yamagishi S, Ueda S, Matsui T, Nakamura K, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17: 983-96.
15. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 2005; 5: 309-22.
16. Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12: 1549-54.
17. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
18. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-7.
19. Tombran-Tink J, Chader CG, Johnson LV. PEDF: Pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-4.
20. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4: 628-36.
21. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu HJ, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
22. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-9.
23. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, et al. Loss of the antiangiogenic pigment epitheliumderived factor in patients with angiogenic eye disease. Diabetes 2002; 50: 2641-5.
24. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003; 65: 186-90.
25. Yamagishi S, Inagaki Y, Nakamura K, et al. Pigment epitheliumderived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497-506.
26. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel antioxidative mechanism of PEDF. Cell Tissue Res 2005; 320: 437-45.
27. Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epitheliumderived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 2006; 71: 222-6.
28. Yamagishi S, Matsui T, Nakamura K, et al. Pigment epitheliumderived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20.
29. Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epitheliumderived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580: 2788-96.
30. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006; 72: 86-90.
31. Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epitheliumderived factor (PEDF) blocks the interleukin-6 signaling to Creactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sci 2006; 79: 1981-7.
32. Yamagishi S, Kikuchi S, Nakamura K, et al. Pigment epitheliumderived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006; 38: 546-8.
33. Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue H. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2. Med Chem 2006; 2: 265-9.
34. Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epitheliumderived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007; 39: 92-7.
35. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 2007; 39: 233-5.
36. Nakamura K, Yamagishi S, Matsui T, et al. Pigment epitheliumderived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007; 170: 2159-70.
37. Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Protein Pept Lett 2007; 14: 615-7.
38. Jinnouchi Y, Yamagishi S, Matsui T, et al. Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 2007; 1167: 92-100.
39. Takenaka K, Yamagishi S, Matsui T, et al. Pigment epitheliumderived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis 2008; 197: 25-33.
40. Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14: 832-5.
41. Yamagishi S, Abe R, Jinnouchi Y, Matsui T, Imaizumi T, Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J Int Med Res 2007; 35: 896-9.
42. Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epitheliumderived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40: 620-5.
43. Yamagishi S, Matsui T, Nakamura K, Takenaka K. Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats. Clin Exp Med 2009; 9: 73-6.
44. Yamagishi S, Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H. Pigment epithelium-derived factor prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009; 25: 266-71.
45. Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med 2010; 10: 267-78.
46. Yabe T, Sanagi T, Yamada H. The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr Mol Med 2010; 10: 259-66.
47. Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2009; 13: 1295-302.
48. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epitheliumderived factor as a multifunctional antitumor factor. J Mol Med (Berl) 2007; 85: 15-22.
49. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006; 12: 497-502.
50. Yamagishi S, Matsui T, Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009; 15: 1027-33.
51. Ueda S, Yamagishi SI, Okuda S. Anti-vasopermeability effects of PEDF in retinal-renal disorders. Curr Mol Med 2010; 10: 279-83.
52. Yamagishi SI, Matsui T. Anti-atherothrombogenic properties of PEDF. Curr Mol Med 2010; 10: 284-91.
53. Yamagishi SI, Matsui T, Kawaguchi T, Sata M. Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders. Curr Med Chem 2010; 17: 1995-2000.
54. Arimura T, Miura S, Sugihara M, Iwata A, Yamagishi S, Saku K. Association between plasma levels of pigment epithelium-derived factor and renal dysfunction in patients with coronary artery disease. Cardiol J 2011; 18: 515-20.
55. Shiga Y, Miura S, Mitsutake R, Yamagishi S, Saku K. Significance of plasma levels of pigment epithelium-derived factor as determined by multidetector row computed tomography in patients with mild chronic kidney disease and/or coronary artery disease. J Int Med Res 2011; 39: 880-90.
56. Tahara N, Yamagishi S, Tahara A, et al. Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis 2011; 219: 311-5.
57. Sugihara M, Miura S, Takamiya Y, et al. Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation. J Renin Angiotensin Aldosterone Syst 2011; 12: 320-5.
58. Iwata A, Miura S, Morii J, Yamagishi S, Saku K. Association between plasma pigment epithelium-derived factor levels and tissue characteristics of coronary plaque using integrated backscatter intravascular ultrasound. Intern Med 2011; 50: 1889-94.
59. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab invest 1994; 70: 138-50.
60. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79.
61. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
62. Yan SF, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007; 7: 699-710.
63. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
64. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14: 979-86.
65. Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010; 17: 4511-20.
66. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. Int J Cardiol 2011; 152: 408-10.
67. Famulla S, Lamers D, Hartwig S, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond) 2011; 35: 762-72.
68. Crowe S, Wu LE, Economou C, et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab 2009; 10: 40-7.
69. Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, Watt MJ. Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes 2011; 60: 1458-66.
70. Fukami K, Yamagishi SI, Okuda S. Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility. Curr Mol Med 2010; 10: 317-20.
71. Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 2447-50.
72. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Inoue H. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 52-6.
73. Yamagishi S, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol Res 2010; 61: 103-7.
74. Nakamura K, Yamagishi S, Yoshida T, et al. Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29. J Int Med Res 2007; 35: 427-32.
75. Kratchmarova I, Kalume DE, Blagoev B, et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics 2002; 1: 213-22.
76. Wang M, Wang JJ, Li J, et al. Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab 2009; 297: E1378-87.
77. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
78. Sabater M, Moreno-Navarrete JM, Ortega FJ, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab 2010; 95: 4720-8.
79. Jenkins A, Zhang SX, Gosmanova A, et al. Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract 2008; 82: e5-7.
80. Yang S, Li Q, Zhong L, Song Y, et al. Serum pigment epitheliumderived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab 2011; 96: 831-6.
81. Chen C, Tso AW, Cheung BM, et al. Plasma concentration of pigment epithelium-derived factor is closely associated with blood pressure and predicts incident hypertension in Chinese: a 10-year prospective study. Clin Endocrinol (Oxf) 2012; 76: 506-13.
82. Chen C, Tso AW, Law LS, et al. Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: a 10-year prospective study. J Clin Endocrinol Metab 2010; 95: 5074-81.
83. Oberbach A, von Bergen M, Blüher S, Lehmann S, Till H. Combined serum proteomic and metabonomic profiling after laparoscopic sleeve gastrectomy in children and adolescents. J Laparoendosc Adv Surg Tech A 2012; 22: 184-8.
84. Böhm A, Ordelheide AM, Machann J, et al. Common genetic variation in the SERPINF1 locus determines overall adiposity, obesity-related insulin resistance, and circulating leptin levels. PLoS One 2012; 7: e34035.
85. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita Y, Imaizumi T. Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. Int J Cardiol 2010; 143: 96-8.
86. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita Y, Inoue H. Serum level of pigment epithelium derived factor (PEDF) is an independent determinant of resting heart rate in Japanese subjects. Int J Cardiol 2009; 136: 245-7.
87. Lashbrook BL, Steinle JJ. Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retina. Auton Neurosci 2005; 121: 33-9.
88. Yamagishi S, Kobayashi K, Yamamoto H. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of cocultured endothelial cells. Biochem Biophys Res Commun 1993; 190: 418-25.
89. Yamagishi S, Hsu CC, Kobayashi K, Yamamoto H. Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. Biochem Biophys Res Commun 1993; 191: 840-6.
90. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51: 3107-12.
91. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002; 296: 877-82.
92. Amano S, Yamagishi S, Inagaki Y, et al. Pigment epitheliumderived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res 2005; 69: 45-55.
93. Yamagishi S, Matsui T, Nakamura K, Inoue H. Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy. Int J Tissue React 2005; 27: 197-202.
94. Yamagishi S, Nakamura K, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T. Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of plateletderived growth factor-B. Microvasc Res 2005; 69: 128-34.
95. Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001; 132: 378-82.
96. Boehm BO, Lang G, Volpert O, et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400.
97. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004; 101: 6605-10.
98. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epitheliumderived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37: 1-12.
99. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294-301.
100. Yokoi M, Yamagishi S, Saito A, et al. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007; 91: 885-7.
101. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003; 44: 4457-64.
102. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 1999; 40: 1808-12.
103. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160: 501-9.
104. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-62.
105. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-7.
106. Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2008; 40: 10-5.
107. Mitamura Y, Takeuchi S, Matsuda A, et al. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2000; 215: 415-8.
108. Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14: 832-5.
109. Harrison DG, Widder J, Grumbach I, Chen W, Weber M, Searles C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006; 259: 351-63.
110. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006, 20: 323-5.
111. Yoshida, Y, Yamagishi S, Matsui T, et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009; 25: 678-86.
112. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Upregulation of vascular endothelial growth factor and downregulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes. Int J Tissue React 2002; 24: 137-42.
113. Wang JJ, Zhang SX, Lu K, et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes 2005; 54: 243-50.
114. Wang JJ, Zhang SX, Mott R, et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 2006; 55: 1678-85.
115. Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end productelicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 2010; 80: 227-32.
116. Maeda S, Matsui T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011; 63: 241-8.
117. Wang JJ, Zhang SX, Mott R, et al. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F1166-73.
118. Jenkins AJ, Zhang SX, Rowley KG, et al. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007; 24: 1345-51.
119. Chen H, Zheng Z, Li R, et al. Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy. Am J Nephrol 2010; 32: 47-56.
120. Motomiya Y, Yamagishi S, Adachi H, Abe A. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem 2006; 52: 1970-1.
121. Fujimura T, Yamagishi S, Ueda S, et al. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant 2009; 24: 1397-406.
122. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009; 42: 1331-46.
123. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005; 25: 193-7.
124. Notari L, Baladron V, Aroca-Aguilar JD, et al. Identification of a lipase-linked cell membrane receptor for pigment epitheliumderived factor. J Biol Chem 2006; 281: 38022-37.
125. Chung C, Doll JA, Gattu AK, et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008; 48: 471-8.
126. Chung C, Shugrue C, Nagar A, et al. Ethanol exposure depletes hepatic pigment epithelium-derived factor, a novel lipid regulator. Gastroenterology, 2009; 136: 331-40.
127. Manitovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
128. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60: 1185-95.
129. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor-alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type. J Exp Med 1992; 177: 1277-86.
130. Nawroth PP, Stern DM. Modulation of endothelial cells hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
131. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 2004; 286: H1001-7.
132. Frey RS, Rahman A, Kefe, JC, Minshall RD, Malik AB. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ Res 2002; 90: 1012-9.
133. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-a-induced NFkappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15: 2423-32.
134. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Cir Res 2000; 86: 494-501.
135. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Cir Res 1999; 85: 753-66.
136. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 2009; 284: 10480-90.
137. Matsui T, Nishino Y, Maeda S, Yamagishi S. PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression. Microvasc Res 2012; 84: 105-8.
138. Kawaguchi T, Yamagishi SI, Sata M. Structure-function relationships of PEDF. Curr Mol Med 2010; 10: 302-11.
139. Baba H, Yonemitsu Y, Nakano T, et al. Cytoplasmic expression aand extracelluar deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2005; 25: 1938-44.
140. Yamagishi SI, Maeda S, Ueda S, Ishibashi Y, Matsui T. Serum pigment epithelium-derived factor levels are independently associated with decreased number of circulating endothelial progenitor cells in healthy non-smokers. Int J Cardiology 2012; doi.org/10.1016/j.ijcard.2012.04.149
141. Longeras R, Farjo K, Ihnat M, Ma JX. A PEDF-derived peptide inhibits retinal neovascularization and blocks mobilization of bone marrow-derived endothelial progenitor cells. Exp Diabetes Res 2012; 2012: 518426.
142. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49:741-52.
143. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Cir Res 2001; 89: E1-7.
144. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
145. Ho TC, Yang YC, Chen SL, et al. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferators-activated receptor gamma. Mol Immunol 2008; 45: 898-909.
146. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006; 47: 3912-8.
147. Monaco C, Andreakos E, Kiiriakidis S, Feldmann M, Paleolog E. T-cell-mediated signaling in imuune, inflammatory and angiogenic process: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004; 3: 35-42.
148. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008; 263: 489-99.
149. Yamagishi S, Matsui T, Ueda S, Takeuchi M. Pigment epitheliumderived factor (PEDF) inhibits diabetes-or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats. Int J Cardiol 2010; 144: 283-5.
150. Yamagishi S, Matsui T, Nakamura K, Takenaka K. Pigment epithelium-derived factor (PEDF) inhibits collagen-induced platelet activation by reducing intraplatelet nitrotyrosine levels. Int J Cardiol 2010; 140: 121-2.
151. Yamagishi S, Matsui T, Nakamura K, Takenaka K. Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats. Clin Exp Med 2009; 9: 73-6.
152. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001; 91: 149-66.
153. Levizki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005; 65: 581-6.
154. Ueda S, Yamagishi S, Matsui T, Jinnouchi Y, Imaizumi T. Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 2011; 178: 591-8.